Compare INMB & GRSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INMB | GRSD |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Jersey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 69.8M |
| IPO Year | 2018 | 2021 |
| Metric | INMB | GRSD |
|---|---|---|
| Price | $2.44 | $1.90 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | ★ 339.7K | 300.5K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $1.63 |
| 52 Week High | $2.50 | $2.41 |
| Indicator | INMB | GRSD |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 52.83 |
| Support Level | $1.16 | $1.82 |
| Resistance Level | $2.50 | $2.07 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 52.51 | 25.00 |
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Grandstand Ltd is the intelligence layer powering informed decisions for consumers and partners across sports, gaming and entertainment. Its brands include OddsJam, OpticOdds, RotoWire, Gambling.com and Casinos.com. The group's partner solutions span sports data, advertising, audience monetization, entertainment, and tickets.